JNJJanssen Research & Development, LLCRunning, no new patients
A Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared With Carboplatin-Pemetrexed, in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Characterized by Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions
Carcinoma, Non-Small-Cell Lung
2Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +2
4 insiders sold shares within a month
Since Aug 17, 2026 · was worth 5, fading over time
Worry score2
Score over time
- Stage
- Phase 3
- Patients
- 308 (final count)
- Started
- Oct 13, 2020
- Main results expected
- May 3, 2023
- Fully finished
- Dec 31, 2027
- Results posted
- May 29, 2024
What counts as success
The trial's main goal(s), called the “primary outcome.”
Progression-Free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 as Assessed by Blinded Independent Central Review (BICR)
Measured over: From randomization to either disease progression or death whichever occurs first (up to 29 months)
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- insider_selling_cluster: base 5, now 2, since 2026-08-17, fades (half-life)
Raw record changes
- none yet
Trial ID NCT04538664 · record last updated 2026-11-03 · checked 2026-11-09 15:47 UTC